Chicago Equity Partners’s Haemonetics HAE Stock Holding History

Chicago Equity Partners’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$1.51M	Sell	15,145 -3,970	-21%	-$430K	0.15%	199
2019 Q4	$2.2M	Sell	19,115 -5,090	-21%	-$616K	0.13%	240
2019 Q3	$3.05M	Buy	24,205 +7,245	+43%	+$920K	0.15%	206
2019 Q2	$2.04M	Sell	16,960 -125	-0.7%	-$12.3K	0.09%	322
2019 Q1	$1.5M	Sell	17,085 -18,200	-52%	-$1.66M	0.06%	410
2018 Q4	$3.53M	Sell	35,285 -11,720	-25%	-$1.23M	0.14%	201
2018 Q3	$5.39M	Sell	47,005 -39,660	-46%	-$4.11M	0.16%	173
2018 Q2	$7.77M	Buy	86,665 +22,000	+34%	+$1.86M	0.24%	119
2018 Q1	$4.73M	Buy	64,665 +44,155	+215%	+$3.03M	0.15%	194
2017 Q4	$1.19M	Buy	+20,510	New	+$1.08M	0.04%	467

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Chicago Equity Partners's HAE Position: Q1 2020 in Review

Chicago Equity Partners reduced its Haemonetics (HAE) stake by 21% in Q1 2020, selling an estimated $430K and leaving 15,145 shares worth $1.51M. The position accounts for 0.15% of the portfolio, ranked #199.

Chicago Equity Partners first reported a position in HAE in Q4 2017 and has held it in 10 quarters since. The position peaked at $7.77M in Q2 2018. 269 funds tracked by Wall St. Rank hold HAE as of Q1 2020.

Chicago Equity Partners held 15,145 shares of Haemonetics worth $1.51M as of Q1 2020.
Chicago Equity Partners sold 3,970 Haemonetics shares in Q1 2020, an estimated $430K.
Haemonetics made up 0.15% of Chicago Equity Partners's portfolio in Q1 2020, its #199 holding.
Chicago Equity Partners first reported a position in Haemonetics in Q4 2017 and has held it in 10 quarters since.
Chicago Equity Partners's Haemonetics position peaked at $7.77M in Q2 2018.
269 funds tracked by Wall St. Rank held Haemonetics as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.